Statins: Epidrugs with effects on endothelial health?

Area of Science:

• Epigenetics
• Pharmacology
• Molecular Biology

Background:

• Epigenetic modifications like DNA methylation and histone alterations are crucial in cellular processes and diseases, including cancer and cardiovascular conditions.
• Statins (HMG-CoA reductase inhibitors) are primary drugs for managing cardiovascular diseases, known for their cholesterol-lowering and other beneficial effects.
• The precise mechanisms behind statins' pleiotropic functions, independent of HMG-CoA reductase inhibition, remain unclear, particularly their impact on epigenetic reprogramming.

Purpose of the Study:

• To review and synthesize existing research on the effects of statins on epigenetic reprogramming.
• To explore the potential role of epigenetic mechanisms in mediating the pleiotropic effects of statins.
• To understand how statins influence epigenetic modifications for potential broader clinical applications.

Main Methods:

• A comprehensive electronic database search was conducted.
• Studies investigating significant effects of statins on epigenetic reprogramming in cell cultures and in vivo models were identified and reviewed.

Main Results:

• Epigenetic mechanisms are integral to cellular development and function.
• Evidence suggests that many of statins' pleiotropic effects are mediated through epigenetic pathways.
• These non-classical, epigenetically-driven effects of statins extend beyond cardiovascular diseases to other conditions, including malignancies.

Conclusions:

• The findings suggest that epigenetic effects contribute significantly to the pleiotropic actions of statins.
• Further clinical validation is required to substantiate these observed epigenetic effects of statins.
• Understanding these mechanisms could expand the therapeutic applications of statin therapy.